Clinical trial · Observational
MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer
A Feasibility Study of MRI in Assessment of Primary Tumor During Chemoradiation for Anal Canal and Perianal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Patient eligibility has limited accrual and patient sample has changed with the change in referral patients.
Summary
Brief summary (as posted)
The purpose of this study is to establish a prospective database of anal canal and perianal cancer patients treated with IMRT and chemotherapy with curative intent at PMH for the purposes of investigating MRI-derived primary tumor parameters. Patients who decide to participate in this study will be treated according to standard treatment policies and radiation therapy planning protocols at Princess Margaret Hospital (PMH) with radiation therapy +/- chemotherapy. IMRT for all treatment phases of radiotherapy has been implemented as standard treatment. Surgery is reserved for salvage treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer Patients | Anal Neoplasm | PROBABILISTIC | 0.70 |
| Perianal Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MRI Scan
- interventionNames
- Other: Magnetic Resonance Imaging (MRI)
Primary outcomes (3)
- measure
- Primary tumor dimensions at simulation and during week 3 and last week of fractionated radiotherapy from MRI
- timeFrame
- 12 months
- measure
- Primary tumor perfusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI
- timeFrame
- 12 months
- measure
- Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI
- timeFrame
- 12 months
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * histological confirmation of invasive primary squamous cell carcinoma or adenocarcinoma of the anal canal or perianal region * treatment with curative intent * patients who are not eligible for chemotherapy and receive IMRT alone are eligible for evaluation * primary anal or perianal cancer evaluable on cross-sectional imaging (CT or MRI) scan * ECOG performance status of 0, 1, or 2 * age \> 18 years * able to provide informed consent Exclusion Criteria: * evidence of distant metastasis (M1) * prior radiation therapy to the pelvis or contraindication to radiotherapy * contraindication to MRI imaging * known allergy to intravenous Gadolinium * renal insufficiency (serum creatinine greater than 150) * serious claustrophobia * cardiac pacemaker * hip prosthesis * major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of imaging study
References
Publications (0)
Data not yet available